RxDoctor Payments Data

Morrisa Gray-Brown, APRN

Psychiatric/Mental Health · Cincinnati, OHNPI 1609275239

Payments from drug & device makers

$2,250in general payments, 2019–2025

Across 118 payments — averaging $19.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$373
  • Indivior Inc.$367
  • Teva Pharmaceuticals USA, Inc.$324
  • Alkermes, Inc.$243
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$233
  • Lundbeck LLC$231
  • plus $478 from 8 others

What the payments were for

  • Food & beverage$2,250100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,250 in reported general payments places this provider in the 75th percentile of 1,808 psychiatric/mental health providers in Ohio.

See all psychiatric/mental health providers in Ohio

Medicare billing

Part B allowed, 2024
$1,953
Medicare patients
11
Services billed
24

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole51$77,272
Invega SustennaPaliperidone Palmitate12$46,484
TrintellixVortioxetine Hydrobromide13$6,442
Fluoxetine Hcl24$1,822
Olanzapine19$1,670
Venlafaxine Hcl ErVenlafaxine Hcl74$1,620
Buspirone Hcl127$1,436
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl39$1,435
Aripiprazole18$1,210
Desvenlafaxine Succinate ErDesvenlafaxine Succinate13$1,186
Trazodone Hcl94$729
Hydroxyzine Hcl17$719
Paliperidone ErPaliperidone11$676
Quetiapine Fumarate58$661
Atomoxetine Hcl13$595

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$94$77,27251 claims
Johnson & JohnsonInvega Sustenna$189$46,48412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,808 psychiatric/mental health providers in Ohio.

Other psychiatric/mental health in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →